Get the latest news, insights, and market updates on ERAS (Erasca, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference being held at the Sheraton New York Times Square in New York, NY. Management will present on Tuesday, September 9, 2025, at 3:20 pm Eastern Time and will al Sep 2, 2025 - $ERAS
Promising Penny Stocks To Consider In August 2025
As the U.S. stock market continues its rally, with major indices like the S&P 500 and Nasdaq hitting new highs, investors are exploring diverse opportunities to capitalize on this momentum. Penny stocks, often associated with smaller or newer companies, remain a compelling area for those looking to uncover hidden value and growth potential. Despite being an older term in the investment lexicon, these stocks can offer intriguing opportunities when backed by robust financials and strategic... Aug 14, 2025 - $ERAS
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $387 million as of June 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, devel Aug 12, 2025 - $ERAS
Top Penny Stocks To Watch In July 2025
As the S&P 500 and Nasdaq Composite surge to new all-time highs, buoyed by a strong jobs report and optimism around trade agreements, investors are exploring diverse opportunities across the stock market. Penny stocks, despite being a somewhat outdated term, still capture the essence of investing in smaller or newer companies that may offer significant growth potential at lower price points. By focusing on those with solid fundamentals and financial resilience, these stocks can present... Jul 3, 2025 - $ERAS
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investig Jun 2, 2025 - $ERAS
Discover May 2025's Top Penny Stocks
Over the last 7 days, the U.S. market has risen by 1.2%, contributing to a 12% increase over the past year, with earnings anticipated to grow by 14% annually. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever; these stocks can provide a mix of affordability and growth potential when paired with strong financials. Below, we'll explore three penny stocks that stand out for their financial strength and resilience in today's... May 30, 2025 - $ERAS
Erasca to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and will also participate in one-on-one investor meetings at each of these conferences. Jefferies Global Healthcare Conference (June 3-5, 2025)Location: Ne May 29, 2025 - $ERAS
Erasca Reports First Quarter 2025 Business Updates and Financial Results
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on dis May 13, 2025 - $ERAS
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway
IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 following strategic decision to pursue partnership opportunities for naporafenib SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, a May 13, 2025 - $ERAS
Erasca to Present at the Bank of America Securities Health Care Conference
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2025 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 14, 2025, at 2:35 pm Pacific Time and will also participate in o May 7, 2025 - $ERAS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple